Phase I trial of gefitinib (ZD1839) in combination with concurrent carboplatin, paclitaxel and radiation therapy in patients with stage III non-small cell lung cancer

D Rischin, B Burmeister, P Mitchell, M Boyer… - Journal of Clinical …, 2004 - ascopubs.org
7077 Background: Gefitinib ('Iressa', ZD1839) enhances tumor radioresponsiveness in
preclinical studies, and is approved as monotherapy in non-small-cell lung cancer (NSCLC) …
被引用次数：32 相关文章

[引用][C] Phase I trial of gefitinib (ZD1839) in combination with concurrent carboplatin, paclitaxel and radiation therapy in patients with stage III non-small cell lung cancer

D Rischin, B Burmeister, P Mitchell, M Boyer… - Journal of Clinical …, 2004 - cir.nii.ac.jp
Phase I trial of gefitinib (ZD1839) in combination with concurrent carboplatin, paclitaxel and
radiation therapy in patients with stage III non-small cell lung cancer | CiNii Research CiNii 国立 …

[引用][C] Phase I trial of gefitinib (ZD1839) in combination with concurrent carboplatin, paclitaxel and radiation therapy in patients with stage III non-small cell lung cancer …

D Rischin, B Burmeister, P Mitchell… - Journal of Clinical …, 2004 - espace.library.uq.edu.au

[引用][C] Phase I trial of gefitinib (ZD1839) in combination with concurrent carboplatin, paclitaxel and radiation therapy in patients with stage III non-small cell lung cancer

D RISCHIN - Proc Am Soc Clin Oncol., 2004 - cir.nii.ac.jp
Phase I trial of gefitinib (ZD1839) in combination with concurrent carboplatin, paclitaxel and
radiation therapy in patients with stage III non-small cell lung cancer | CiNii Research CiNii 国立 …